Human LEPR/CD295/LEP-R ORF/cDNA clone-Lentivirus particle (NM_002303.6)

Cat. No.: vGMLV001081

Pre-made Human LEPR/CD295/LEP-R Lentiviral expression plasmid for LEPR lentivirus packaging, LEPR lentivirus production, overexpression stable cell line development, cell transient transfection and gene delivery targeting T/B/NK cells, macrophages, cardiomyocytes, hepatocytes, and neurons.

The GM Vector Core (GMVC) specializes in custom lentivirus development and offers a range of lentivirus manufacturing solutions, leveraging state-of-the-art processes. Learn more about our services.

Target products collection

Go to LEPR/Leptin R/CD295/LEPR/CD295 products collection>>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdf MSDS
pdf Datasheet

Product information

Catalog No. Product Name lentivirus Grade lentivirus quantity
vGMLV001081 Human LEPR Lentivirus particle Pilot Grade 1.0E+8TU
5.0E+8TU
1.0E+9TU
Research Grade 1.0E+8TU
5.0E+8TU
1.0E+9TU
GMP-like Grade inquiry
GMP Grade inquiry


Product Description

Catalog ID vGMLV001081
Gene Name LEPR
Accession Number NM_002303.6
Gene ID 3953
Species Human
Product Type Lentivirus particle (overexpression)
Insert Length 3498 bp
Gene Alias CD295,LEP-R,LEPRD,OB-R,OBR
Fluorescent Reporter Null
Mammalian Cell Selection Puromyocin
Fusion Tag 3xflag (C-Terminal)
Promoter CMV
Resistance Amplicin
ORF Nucleotide Sequence ATGATTTGTCAAAAATTCTGTGTGGTTTTGTTACATTGGGAATTTATTTATGTGATAACTGCGTTTAACTTGTCATATCCAATTACTCCTTGGAGATTTAAGTTGTCTTGCATGCCACCAAATTCAACCTATGACTACTTCCTTTTGCCTGCTGGACTCTCAAAGAATACTTCAAATTCGAATGGACATTATGAGACAGCTGTTGAACCTAAGTTTAATTCAAGTGGTACTCACTTTTCTAACTTATCCAAAACAACTTTCCACTGTTGCTTTCGGAGTGAGCAAGATAGAAACTGCTCCTTATGTGCAGACAACATTGAAGGAAAGACATTTGTTTCAACAGTAAATTCTTTAGTTTTTCAACAAATAGATGCAAACTGGAACATACAGTGCTGGCTAAAAGGAGACTTAAAATTATTCATCTGTTATGTGGAGTCATTATTTAAGAATCTATTCAGGAATTATAACTATAAGGTCCATCTTTTATATGTTCTGCCTGAAGTGTTAGAAGATTCACCTCTGGTTCCCCAAAAAGGCAGTTTTCAGATGGTTCACTGCAATTGCAGTGTTCATGAATGTTGTGAATGTCTTGTGCCTGTGCCAACAGCCAAACTCAACGACACTCTCCTTATGTGTTTGAAAATCACATCTGGTGGAGTAATTTTCCAGTCACCTCTAATGTCAGTTCAGCCCATAAATATGGTGAAGCCTGATCCACCATTAGGTTTGCATATGGAAATCACAGATGATGGTAATTTAAAGATTTCTTGGTCCAGCCCACCATTGGTACCATTTCCACTTCAATATCAAGTGAAATATTCAGAGAATTCTACAACAGTTATCAGAGAAGCTGACAAGATTGTCTCAGCTACATCCCTGCTAGTAGACAGTATACTTCCTGGGTCTTCGTATGAGGTTCAGGTGAGGGGCAAGAGACTGGATGGCCCAGGAATCTGGAGTGACTGGAGTACTCCTCGTGTCTTTACCACACAAGATGTCATATACTTTCCACCTAAAATTCTGACAAGTGTTGGGTCTAATGTTTCTTTTCACTGCATCTATAAGAAGGAAAACAAGATTGTTCCCTCAAAAGAGATTGTTTGGTGGATGAATTTAGCTGAGAAAATTCCTCAAAGCCAGTATGATGTTGTGAGTGATCATGTTAGCAAAGTTACTTTTTTCAATCTGAATGAAACCAAACCTCGAGGAAAGTTTACCTATGATGCAGTGTACTGCTGCAATGAACATGAATGCCATCATCGCTATGCTGAATTATATGTGATTGATGTCAATATCAATATCTCATGTGAAACTGATGGGTACTTAACTAAAATGACTTGCAGATGGTCAACCAGTACAATCCAGTCACTTGCGGAAAGCACTTTGCAATTGAGGTATCATAGGAGCAGCCTTTACTGTTCTGATATTCCATCTATTCATCCCATATCTGAGCCCAAAGATTGCTATTTGCAGAGTGATGGTTTTTATGAATGCATTTTCCAGCCAATCTTCCTATTATCTGGCTACACAATGTGGATTAGGATCAATCACTCTCTAGGTTCACTTGACTCTCCACCAACATGTGTCCTTCCTGATTCTGTGGTGAAGCCACTGCCTCCATCCAGTGTGAAAGCAGAAATTACTATAAACATTGGATTATTGAAAATATCTTGGGAAAAGCCAGTCTTTCCAGAGAATAACCTTCAATTCCAGATTCGCTATGGTTTAAGTGGAAAAGAAGTACAATGGAAGATGTATGAGGTTTATGATGCAAAATCAAAATCTGTCAGTCTCCCAGTTCCAGACTTGTGTGCAGTCTATGCTGTTCAGGTGCGCTGTAAGAGGCTAGATGGACTGGGATATTGGAGTAATTGGAGCAATCCAGCCTACACAGTTGTCATGGATATAAAAGTTCCTATGAGAGGACCTGAATTTTGGAGAATAATTAATGGAGATACTATGAAAAAGGAGAAAAATGTCACTTTACTTTGGAAGCCCCTGATGAAAAATGACTCATTGTGCAGTGTTCAGAGATATGTGATAAACCATCATACTTCCTGCAATGGAACATGGTCAGAAGATGTGGGAAATCACACGAAATTCACTTTCCTGTGGACAGAGCAAGCACATACTGTTACGGTTCTGGCCATCAATTCAATTGGTGCTTCTGTTGCAAATTTTAATTTAACCTTTTCATGGCCTATGAGCAAAGTAAATATCGTGCAGTCACTCAGTGCTTATCCTTTAAACAGCAGTTGTGTGATTGTTTCCTGGATACTATCACCCAGTGATTACAAGCTAATGTATTTTATTATTGAGTGGAAAAATCTTAATGAAGATGGTGAAATAAAATGGCTTAGAATCTCTTCATCTGTTAAGAAGTATTATATCCATGATCATTTTATCCCCATTGAGAAGTACCAGTTCAGTCTTTACCCAATATTTATGGAAGGAGTGGGAAAACCAAAGATAATTAATAGTTTCACTCAAGATGATATTGAAAAACACCAGAGTGATGCAGGTTTATATGTAATTGTGCCAGTAATTATTTCCTCTTCCATCTTATTGCTTGGAACATTATTAATATCACACCAAAGAATGAAAAAGCTATTTTGGGAAGATGTTCCGAACCCCAAGAATTGTTCCTGGGCACAAGGACTTAATTTTCAGAAGCCAGAAACGTTTGAGCATCTTTTTATCAAGCATACAGCATCAGTGACATGTGGTCCTCTTCTTTTGGAGCCTGAAACAATTTCAGAAGATATCAGTGTTGATACATCATGGAAAAATAAAGATGAGATGATGCCAACAACTGTGGTCTCTCTACTTTCAACAACAGATCTTGAAAAGGGTTCTGTTTGTATTAGTGACCAGTTCAACAGTGTTAACTTCTCTGAGGCTGAGGGTACTGAGGTAACCTATGAGGACGAAAGCCAGAGACAACCCTTTGTTAAATACGCCACGCTGATCAGCAACTCTAAACCAAGTGAAACTGGTGAAGAACAAGGGCTTATAAATAGTTCAGTCACCAAGTGCTTCTCTAGCAAAAATTCTCCGTTGAAGGATTCTTTCTCTAATAGCTCATGGGAGATAGAGGCCCAGGCATTTTTTATATTATCAGATCAGCATCCCAACATAATTTCACCACACCTCACATTCTCAGAAGGATTGGATGAACTTTTGAAATTGGAGGGAAATTTCCCTGAAGAAAATAATGATAAAAAGTCTATCTATTATTTAGGGGTCACCTCAATCAAAAAGAGAGAGAGTGGTGTGCTTTTGACTGACAAGTCAAGGGTATCGTGCCCATTCCCAGCCCCCTGTTTATTCACGGACATCAGAGTTCTCCAGGACAGTTGCTCACACTTTGTAGAAAATAATATCAACTTAGGAACTTCTAGTAAGAAGACTTTTGCATCTTACATGCCTCAATTCCAAACTTGTTCTACTCAGACTCATAAGATCATGGAAAACAAGATGTGTGACCTAACTGTGTAA
ORF Protein Sequence MICQKFCVVLLHWEFIYVITAFNLSYPITPWRFKLSCMPPNSTYDYFLLPAGLSKNTSNSNGHYETAVEPKFNSSGTHFSNLSKTTFHCCFRSEQDRNCSLCADNIEGKTFVSTVNSLVFQQIDANWNIQCWLKGDLKLFICYVESLFKNLFRNYNYKVHLLYVLPEVLEDSPLVPQKGSFQMVHCNCSVHECCECLVPVPTAKLNDTLLMCLKITSGGVIFQSPLMSVQPINMVKPDPPLGLHMEITDDGNLKISWSSPPLVPFPLQYQVKYSENSTTVIREADKIVSATSLLVDSILPGSSYEVQVRGKRLDGPGIWSDWSTPRVFTTQDVIYFPPKILTSVGSNVSFHCIYKKENKIVPSKEIVWWMNLAEKIPQSQYDVVSDHVSKVTFFNLNETKPRGKFTYDAVYCCNEHECHHRYAELYVIDVNINISCETDGYLTKMTCRWSTSTIQSLAESTLQLRYHRSSLYCSDIPSIHPISEPKDCYLQSDGFYECIFQPIFLLSGYTMWIRINHSLGSLDSPPTCVLPDSVVKPLPPSSVKAEITINIGLLKISWEKPVFPENNLQFQIRYGLSGKEVQWKMYEVYDAKSKSVSLPVPDLCAVYAVQVRCKRLDGLGYWSNWSNPAYTVVMDIKVPMRGPEFWRIINGDTMKKEKNVTLLWKPLMKNDSLCSVQRYVINHHTSCNGTWSEDVGNHTKFTFLWTEQAHTVTVLAINSIGASVANFNLTFSWPMSKVNIVQSLSAYPLNSSCVIVSWILSPSDYKLMYFIIEWKNLNEDGEIKWLRISSSVKKYYIHDHFIPIEKYQFSLYPIFMEGVGKPKIINSFTQDDIEKHQSDAGLYVIVPVIISSSILLLGTLLISHQRMKKLFWEDVPNPKNCSWAQGLNFQKPETFEHLFIKHTASVTCGPLLLEPETISEDISVDTSWKNKDEMMPTTVVSLLSTTDLEKGSVCISDQFNSVNFSEAEGTEVTYEDESQRQPFVKYATLISNSKPSETGEEQGLINSSVTKCFSSKNSPLKDSFSNSSWEIEAQAFFILSDQHPNIISPHLTFSEGLDELLKLEGNFPEENNDKKSIYYLGVTSIKKRESGVLLTDKSRVSCPFPAPCLFTDIRVLQDSCSHFVENNINLGTSSKKTFASYMPQFQTCSTQTHKIMENKMCDLTV

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    Category Cat No. Products Name
    Biosimilar GMP-Bios-ab-343 Pre-Made Mibavademab biosimilar, Whole mAb, Anti-LEPR Antibody: Anti-CD295/OB-R/OBR therapeutic antibody
    Target Antibody GM-Tg-g-T17163-Ab Anti-LEPR/ CD295/ LEP-RD functional antibody
    Target Antigen GM-Tg-g-T17163-Ag LEPR protein
    ORF Viral Vector pGMLV001081 Human LEPR Lentivirus plasmid
    ORF Viral Vector vGMLV001081 Human LEPR Lentivirus particle


    Target information

    Target ID GM-T17163
    Target Name LEPR/Leptin R/CD295
    Gene Group Identifier
    （Target Gene ID in Homo species)         		3953
    Gene ID 100069504 (Equus caballus), 101085646 (Felis catus), 16847 (Mus musculus), 24536 (Rattus norvegicus)
    3953 (Homo sapiens), 450207 (Canis lupus familiaris), 497205 (Bos taurus), 574126 (Macaca mulatta)
    Gene Symbols & Synonyms LEPR,Lepr,OBR,db,Obr,obl,B219,LEP-R,Leprb,Modb1,LEPROT,OB-RGRP,diabetes,obese-like,Fa,OB-R,CD295,LEPRD,ObRb,Ob-R,Ob-RM
    Target Alternative Names B219,CD295,Fa,HuB219,LEP-R,LEPR,LEPRD,LEPROT,Lepr,Leprb,Leptin R,Leptin receptor,Modb1,OB receptor (OB-R),OB-R,OB-RGRP,OBR,Ob-R,Ob-RM,ObRb,Obr,db,diabetes,obese-like,obl
    Uniprot Accession P48356,P48357,Q62959,Q9MYL0
    Additional SwissProt Accessions: P48356,Q62959,P48357,Q9MYL0
    Uniprot Entry Name
    Protein Sub-location Secreted Protein/Potential Cytokines
    Category Therapeutics Target, INN Index
    Disease cancer, Prostate Cancer
    Disease from KEGG Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, JAK-STAT signaling pathway, Adipocytokine signaling pathway
    Gene Ensembl ENSECAG00000013863, ENSMUSG00000057722, ENSG00000116678, ENSCAFG00845029124, ENSBTAG00000005910, ENSMMUG00000003265
    Target Classification Cytokine Receptor


    About GMVC

    GDU

    GMVC (GM Vector Core) is GeneMedi’s unique platform for QbD Viral vectors Processes development and manufacturing. In GMVC, our core expertise lies in the tailored production of viral vectors, including adeno-associated virus (AAV), lentivirus, and adenovirus. Our state-of-the-art facilities are equipped for scalable manufacturing, ensuring high-quality viral vector production to meet both research and therapeutic needs. Our expert team specializes in process development, leveraging innovative technology and extensive industry knowledge to provide clients with tailored solutions that exceed expectations. GMVC will be the ideal partner for scientists and healthcare professionals seeking reliable and efficient viral vector production services.